# US 8,277,805 B2 · Methods for treating or inhibiting thromboembolic disorders or for inhibiting coagulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,805 B2
- Document ID: US8277805B2
- Status: Granted
- Kind: B2
- Application number: 12/732,556
- Filed: 2010-03-26
- Published: 2011-03-24
- Granted: 2012-10-02
- Earliest claimed: 2003-08-18
- Assignees: Life Sciences Research Partners
- Inventors: Jean-Marie Saint-Remy; Marc Jacquemin
- Web page: https://patentgrep.com/patent/US8277805B2

## CPC

- C07K 16/36: against blood coagulation factors
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 31/04: Antibacterial agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.

## Claims

### Claim 1

A method for treatment of a thromboembolic disorder or for inhibition of coagulation, said method comprising administering an effective dose of an inhibitory antibody against Factor VIII or fragment thereof comprising the immunoglobulin variable light chain CDR1, CDR2 and CDR3 regions depicted in SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38 respectively, and comprising the immunoglobulin variable heavy chain CDR1, CDR2 and CDR3 regions with SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 35 respectively, wherein the glycosylation site at positions 3 and/or 5 in the CDR1 region of the heavy chain is mutated, or wherein Asn at position 3 in the CDR1 region of the variable heavy chain is deglycosylated, and wherein said administering results in said treatment of said thromboembolic disorder or in said inhibition of coagulation.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said mutation of the glycosylation site in the CDR1 region of the heavy chain is the change of Asn into Gln, Glu or Asp at position 3 in said CDR1 region.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said mutation of the glycosylation site in the CDR1 region of the heavy chain is the change is the change of Thr into Ala at position 5 in said CDR1 region.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said mutation of the glycosylation site in the CDR1 region of the heavy chain is the change of Asn into Gln, Glu or Asp at position 3 and the change of Thr into Ala at position 5 in said CDR1 region.

### Claim 5 (depends on 1)

The method according to claim 1 further comprising concomitant administration of a drug(s) inhibiting platelet aggregation.

### Claim 6 (depends on 5)

The method according to claim 5 wherein said drug(s) inhibiting platelet aggregation, is(are) selected from the group consisting of aspirin, abciximab or a thrombolytic agent.

### Claim 7 (depends on 6)

The method according to claim 6 wherein said thrombolytic agent is selected from the group consisting of tissue plasminogen activator, staphylokinase and microplasmin.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the thromboembolic disorder to be treated is selected from the group consisting of deep vein thrombosis, pulmonary embolism secondary to surgical intervention, chronic hereditary thrombophilia and acquired thrombophilia.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the thromboembolic disorder to be treated is selected from the group consisting of deep vein thrombosis, pulmonary embolism, stroke, atrial fibrillation, non Q wave myocardial infarct, non ST elevated myocardial infarct, unstable angina, sepsis and SIRS.
